SUMMARY. We have developed methods for the measurement of the medium-chain fatty acids octanoate, decanoate and cis-4-decenoate and the acylglycines nhexanoylglycine (HG) and 3-phenylpropionylglycine (PPG) in blood spots using gas chromatography and mass spectrometry. Normal ranges were obtained for octanoate and decanoate. HG, PPG and cis-4-decenoic acid were not detected in control blood spots. In blood spots from nine patients (including two newborn) with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, all metabolites were present in elevated concentrations although PPG was close to the detection limits and there was overlap for octanoate and decanoate. The lack of detection of cis-4-decenoic acid and HG in controls suggests that these are the metabolites of choice for blood spot identification of infants with MCAD deficiency.
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a recently described disorder of the mitochondrial oxidation of straight-chain fatty acids.' It is inherited as an autosomal recessive condition which is present in one in 10 000 to one in 20000 individuals of Northern European descent and is particularly prevalent in the UK.2-4 Patients with MCAD deficiency became symptomatic with prolonged fasting or reduced food intake and develop symptoms of hepatic encephalopathy and a Reye-like illness, in some cases leading to sudden unexpected death.~- 7 Patients who are recognized presymptomatically and who are clinically managed to avoid fasting. or patients who are not subjected to prolonged fasting and/or infection are developmentally normal. 7 Treatability, coupled to the high 
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incidence of MCAD deficiency in a selected population make the disorder a good candidate for screening of that population. There are a number of possible routes to achieve this goal including molecular analysis of the common mutation (an A to G base transition in position 985 of the cDNA has been found in 90070 of all mutant alleles investigated so far),2-4 or analysis of one or more of the characteristic rnetabolites.v? The feasibility for analysing the molecular defect in neonatal blood spots is established. However, this approach will only be of value in identifying the 80070 of MCAD deficient patients homozygous for the common mutation. Subjects and samples Blood spots were collected from nine patients with molecular and/or enzyme confirmed MCAD deficiency. They ranged from two newborns (siblings of previously diagnosed cases) to 2 years of age. One patient (No.9) was acutely ill at the time of sample collection all others were clinically well. Samples were collected onto standard phenylketonuria blood spot screening cards, air dried, sealed under vacuum in plastic bags and stored at 4°C until analysis. All samples were analysed within 6 months of collection. Control cards, were collected from the Pennsylvania Newborn Screening Laboratory after routine screening procedures were completed and with storage at 4°C for 3-6 months prior to analysis. Ten samples were obtained from infants aged 2 months to 19 months to control for the older MCAD subjects.
Sample preparation Discs were punched from the cards using a standard \4 in. punch. Typically the filter blood spots were of a sufficient size to punch out three to four discs weighing approximately 30 mg in total. All samples were weighed. Two sets of discs of approximate weight 30 mg were punched from each card. The discs were cut into small pieces using scissors and placed in a glass test tube. Internal standards were added to each tube including 20 nmol of undecanoic acid (200 iLL of a solution containing 100 iLmol/L) and 10 iLg (58 nmol) of n-hexanoyl-[ 1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] and 10 iLg (48 nmol) of 3-phenylpropionyl [2_ 13C,15N] glycine. To one tube 1 mL of distilled water was added and to the second 1 mL of 5M potassium hydroxide (to hydrolyse the carnitine and glucuronide esters of medium-chain fatty acids). These samples were maintained at 25°C for 1 h and constantly swirled. After 1 h 1 mL of water was added to the first tube and 1 mL of 5M hydrochloric acid was added to neutralize the second. Both samples were acidified to pH 2·0 by the dropwise addition of 5M hydrochloric acid, typically four to five drops. Five MCAD deficient patient samples were analysed only after alkaline hydrolysis due to sample shortage. Without removing the filter paper, the samples were extracted three times by vortex mixing with 3 mL ethyl acetate and three times with 3 mL diethyl ether. The pooled solvent extracts were evaporated to dryness under a stream of nitrogen gas at 25°C in a 10 mL pyrex tube. The trimethylsilylderivatives were made by the addition of 50 iLL of bis(trimethylsilyl)trifluoroacetamide containing 1070 trimethylchlorosilane. (Supelco, Bellefonte, Pennsylvania) and 50 ILL of ethylacetate, sealing with a teflon coated liner and heating at 70°C for 30 min.
Gas chromatography/mass spectrometry One microlitre samples of derivatized extract were injected onto a 25 m x 0·2 mm (ID) ultra two capillary column fitted into a series 5971A GC/MS (both from Hewlett-Packard, Palo Alto, CA, USA). The initial column temperature was held at 70°C for 5 min after which the temperature was programmed to increase by 6°C/min to a final temperature of 275°C, which was held for 5 min. The injection and interface temperatures were 250°C and 300°C, respectively.
The effluent was selectively monitored for the ions of mass/charge ratio (m/z) of 201,227,229 and 243 for the characteristic M-I5 ions of octanoate, decanoate, cis-4-decenoate and undecanoate respectively and m/z 230,232,351 and 353 for characteristic ions of HG, stable isotope labelled HG, PPG and stable isotope labelled PPG, respectively. Standard curves were generated for octanoate and decanoate using the abundance of the M-I5 ions of authentic standards and undecanoate as internal standard. Quantitation of cis-4-decenoate was made relative to the decanoate standard curve. This assumes comparable extraction efficiency of the four medium-chain fatty acids in our system. Recovery of both octanoate and decanoate in this system was 100070, therefore because of the chemical similarities it is reasonable to assume that cis-4-decenoate recovers 100070. The identity of cis-4-decenoate was confirmed by electron impact GC/MS analysis in the scan mode. The spectrum obtained corresponded to the published spectrum of the authentic compound and not to a closely chromatographing as-yet unidentified compound which also has an apparent molecular weight of 242. 10 ,11 Quantitation of HG and PPG was by stable isotope dilution analysis. Standard curves were generated using the unlabelled and labelled HG and PPG compounds.
Blanks consisting of filter spots in which no blood was added were anlysed for all compounds. Results are expressed as concentration of metabolite per unit weight of filter blood spot, and assumes equal distribution of blood throughout all blood spots.
RESULTS
Using 25 p.L vol of aqueous standard solutions (equivalent to approximately 25 mg of blood spot) we found that the assay for octanoate and decanoate was linear down to 0 . 2 p.mol/L (equivalent to approximately o·2 nmol/g blood spot) and HG and PPG was linear down to 0·10 p.mol/L equivalent to approximately 0'10 nmol/g of blood spot. Table 1 lists the levels of blood spot metabolites in nine patients with MeAD deficiency, four before and after alkaline hydrolysis of the blood spots, and five after alkaline hydrolysis only. It can be seen that only cis-4-decenoate and HG were consistently elevated in all patient samples. For the three medium-chain fatty acids alkaline hydrolysis increased the measured level in all but one sample. This increase would be anticipated as these compounds are partially circulated as the acylcarnitine and glucuronide esters. Alkaline hydrolysis using the present conditions did not appear to have an effect on acylglycine levels. In three patient samples we were not able to detect PPG in our system suggesting that we are reaching the limit of sensitivity for this analyte.
In the patients there was a wide range of levels for all three fatty acids following alkaline hydrolysis ranging from 10· 5-206 p.mol/g blood spot (octanoate), 1O·0-1l2·2JLmolig (decanoate) and 0'81-82'6JLmolig (cis-4-decenoate). When compared to the normal ranges derived from age matched, storage compatible, blood spots (either neonatal or infant controls) most patient levels were in excess of the highest control level. However, there was some overlap of the normal and patient levels for both octanoate and decanoate. Of particular importance is the observation that cis-4-decenoic acid is present in all MCAD deficient samples, and is not detectable at all in our control samples. In this series of experiments we used a selected ion monitoring procedure. The sensitivity could be further enhanced using stable isotope dilution analysis and selected ion monitoring should a stable isotope labelled fatty acid become available.
For the acylglycine excretion, HG was elevated in all samples and PPG in most. However, we could not detect PPG on three occasions which suggests that we are reaching the limits of detection in the present system or that PPG is not a sufficiently sensitive marker for MCAD deficiency using the present analytical techniques.
DISCUSSION
The high incidence of MCAD deficiency in Northern Europeans, particularly in the UK, coupled to the treatability, make this a desirable disorder to consider selected population screening. There are a number of potential techniques that may be applied. Molecular analysis has demonstrated that 800/0 of patients are homozygous for a single common mutation (A985G)2-4 and that many of the remaining 20% are heterozygous for that mutation. This has led to the development of a simple molecular strategy based upon the presence of an NCo I restriction enzyme cutting site in the mutated allele." This strategy, however simple, will detect homozygous MCAD deficiency only in 80% of cases. Without performing sequence analysis it is not yet possible to readily determine whether heterozygotes for A985G have a second defective allele. This reduces the sensitivity of the molecular analysis as a screening tool. The metabolic analysis would be predicted to have greater sensitivity as all patients should present with abnormal metabolite patterns irrespective of the mutation. The metabolite of choice has not yet been established. One approach has been the analysis of acylcarnitines in blood spots using either fast atom bombardment tandem mass spectrometry or radioisotope exchange HPLC.I3-15 In this present study, we have investigated the feasibility of using blood spot samples to measure other characteristic metabolites including medium-chain fatty acids, before and after the alkaline hydrolysis, using selected ion monitoring GC/MS and acylglycines (HG and PPG) using stable isotope dilution GC/MS analysis.
We have demonstrated analytical linearity for medium-chain fatty acids down to O' 2 JLmoliL and for acylglycines to O' I JLmoliL. This has allowed us to develop normal ranges for octanoate and decanoate in newborn screening cards. One limitation of the present sensitivity limits is that the analyses require several holes to be punched from the screening card. It also assumes even distribution of the blood throughout the filter spot, as do other screening procedures including those for phenylketonuria. This sample requirement limitation may possibly be overcome by the use of larger mass spectrometers in which increased sensitivity may allow the analysis of possibly a single hole punched from the card. However, this would add considerably to both cost, in terms of capital outlay, and complexity of the analysis.
Our results show that there are elevated levels of the naturally occurring medium-chain fatty acids octanoate and decanoate in blood spots collected from most patients with MCAD deficiency. Cis-4-decenoic acid was not detectable at all in our control samples but present in all of our patients. The data is comparable to that of Heales et al." who detected levels of cis-4-decenoate and octanoate in plasma up to 150 JLmoliL in MCAD deficient patients. Our data suggests that of fatty acids, cis-4-decenoic acid may have the greatest specificity for MCAD deficiency in agreement with the suggestion of others. 9 , 16-17 Prior hydrolysis of blood spots in order to release fatty acids from esterification resulted in increased levels of octanoic, decanoic and cis-4-decenoic acid in the MCAD patients. We suggest that alkaline hydrolysis prior to sample analysis should be incorporated into any analytical programs. For the measurement of HG alone, prior hydrolysis may be unnecessary.
Our study both compliments and extends the recent data of Heales and Leonard? who looked specifically at cis-4-decenoate levels of dried blood spots. Our data for this metabolite are similar but there are a number of methodological differences between this study and our own. In particular, our method included a solvent extraction procedure following alkaline hydrolysis of fatty acids. Theoretically the extraction process should reduce potential non-extractable background interference. However, non-extraction procedures may account for the apparent increased sensitivity in the method of Heales and Leonard. They also reported reduced stability of cis-4-decenoate on sample storage at room temperature. Our samples were stored at 4°C in vacuum pack bags and could easily discriminate MCAD deficiency after 6 months of storage. Finally, Heales and Leonard could detect measurable cis-4-decenoic acid in 40% of their control group, we could not detect this metabolite at all in controls. This study did not use neonatal controls. It is possible that in newborns clS-4-decenoate is undetectable by both methods as its precursor linoleic acid is an essential fatty acid for anabolic processes such as membrane synthesis. However, we were unable to detect clS-4-decenoate in samples from normal infants up to 2 years of age suggesting that sensitivity may account for the discrepancy.
There has been very little documented experience regarding the measurement of acylglycines in blood samples. In a single post-mortem blood sample from a patient with MCAD deficiency and homozygous for A985G mutation we detected measurable amounts of HG but no PPG. 18 We have also measured a plasma and a cord blood HG level in two asymptomatic MCAD deficient patients (one homozygous A985G and one with neither allele expressing the A985G mutationmolecular analysis by Dr K Tanaka (YaleUniversity Medical Center, USA). Using 100 iLL of samples these levelswere 107iLg/L [ (620 nmol/L)(plasma) ] and 36 iLg/L [(209 nmol/L)(cord blood)], respectively. In these samples we could not detect PPG in blood. This data suggested that the measurement of HG in blood spots would be in the range detectable by our system. In the present study alkaline hydrolysis did not affect acylglycine measurement for either HG or PPG. We could not detect PPG in three samples which may suggest that for this metabolite we are working closer to the limit of sensitivity. This suggests that HG may be the acylglycine of choice for the detection of MCAD deficiency. Using our system, it should be possible to measure both HG and cis-4-decenoic acid in the same sample following alkaline hydrolysis.
In our present studies we did not look at the stability of these compounds in blood spots. There is some evidence that cis-4-decenoic acid levels decline on storage of whole blood. II For the purpose of this study cis-4-decenoic acid was sufficiently stable to be able to detect MCAD deficiency with up to 6 months of storage. Any Ann Clin Biochem 1994: 31 loss of analyte (either cis-4-decenoic acid or HG) did not effect our ability to diagnose the disorder. Clearly, long-term stability studies will be necessary if newborn screening becomes a feasible prospect.
In conclusion, we have developed methods for the analysis of a number of metabolites found in MCAD deficiency in blood spots. The methods are sufficiently sensitive to detect metabolites in 30 mg of weighed blood spot. CIS-4-decenoic acid, by virtue of its non-detectability in normal blood spots appears to be the metabolite of choice. Its measurement could possibly be coupled to HG measurement and/or molecular analysis for secondary confirmation of a positive result. Whereas the utility of population screening remains to be shown, this study has shown that screening for MCAD deficiency from blood spots is analytically feasible. A combination of molecular and metabolite measurements may together provide the sensitivity and specificity for such an undertaking.
